+0.140 (+1.84%)
Range 7.500 - 7.990   (6.53%)
Open 7.610
Previous Close 7.600
Buy Price 7.740
Buy Volume 8
Sell Price 7.760
Sell Volume 11
Volume 2,493,825
Value -
Measurement Type Value
EPS (USD) -0.327
Trailing EPS (USD) -0.329
NAV (USD) 1.332
Cash In Hand (USD) 1.213
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.706
Price / Cash In Hand 6.265
Issued & Paid-up Shares 91,535,300
Treasury Shares -
Market Cap (M) 695.668
Par Value (USD) n.a.
Beta - 75 Days -0.523
R-Squared - 75 Days(%) 0.45
Beta - 500 Days 0.601
R-Squared - 500 Days(%) 0.29
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 25 Jun 2021 02:17.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 03 Aug 2021
View All Events


Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).

Loading Chart...